Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
MW-150
Cat. No.:
OB0225LY-0323
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
MW-150 is a small molecule compound with neuroprotective properties that inhibits apoptosis by modulating cell signaling pathways.
Synonym:
MW01-18-150SRM; 1628502-91-9; 6-(4-Methylpiperazin-1-yl)-3-(Naphthalen-2-yl)-4-(Pyridin-4-yl)pyridazine; 6-(4-Methyl-1-piperazinyl)-3-(2-naphthalenyl)-4-(4-pyridinyl)-pyridazine; 6-(4-Methylpiperazin-1-yl)-3-naphthalen-2-yl-4-pyridin-4-ylpyridazine
CAS No.:
1628502-91-9
Compound CID:
86270361
Formula:
C24H23N5
Formula Weight:
381.47
Specification
Relative Density:
1.202 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
MW-150 can be used in neuroscience research or play an important role in modeling neurodegenerative diseases.
Library Information
Targets:
p38 MAPK
Receptors:
p38α
Pathways:
MAPK; Autophagy
Plate Number:
AOCL-5
Plate Location:
b7
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
6.25 mg/mL; 16.38 mM
